Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averagePfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of 2025 Form 10-K biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $14.85BThe company’s own SEC segment disclosure.
- Eliquis$2.17B15%
- Prevnar Prevenar Family$1.69B11%
- Vyndaqel$1.60B11%
- Ibrance$1.01B7%
- All Other Hospital And Biosimilars$953.0M6%
- Other Primary Care Products$654.0M4%
- Other (31)$6.77B46%
Pfizer (PFE) reported revenue of $15.0B in Q2 2026 (quarter ended June 28, 2026), up 2.6% from the same quarter a year earlier. That came with a gross margin of 73% and net loss of $248M. For the full year FY2025, revenue was $62.6B (−1.6% year on year) and net income $7.77B. Its largest product in 2026-Q1 was Eliquis at $2.17B, 15% of the disclosed total, just ahead of Prevnar Prevenar Family at 11%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - General
Ranks #14 of 16 by Smart Score